BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Isogenica Limited Secures European Framework 7 Grant Worth Up to EURO 700,000


5/8/2012 2:00:10 PM

Cambridge, UK, 8 April 2012 Isogenica Ltd today announced that it had been successful in securing a Framework 7 grant for €700,000 over the next three years, part of a €5.55 million project with consortium grant funding of €3.99 million. The grant commenced in January 2012.

The 10 consortium members are Apogenix GmbH, Biametrics GmbH, Center for Advanced Bioanalysis, German Cancer Research Centre, Isogenica, Karlsruher Institute for Technology (KIT), Microsystems LTD, PEPperPRINT, Technical University of Varna, The MRC Weatherall Institute of Molecular Medicine (University of Oxford). The project will use Isogenica’s CIS display techniques combined with high-throughput sequencing to screen hundreds of trillions of peptides and to identify up to 100,000 peptide hits against target proteins. The consortia will apply additional technologies to develop an advanced system for ‘deep’ screening of peptide libraries against therapeutic targets. Kevin Matthews, CEO, Isogenica, commented: “We are delighted that the quality of this project proposal has been recognised and funded. The consortium partners are committed to improving the efficiency of peptide lead discovery and we believe this project brings that goal one step nearer.”

About Isogenica

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display. Founded in 2000, and based at Chesterford Research Park near Cambridge, UK, Isogenica has developed a unique capability in the field of protein engineering. Isogenica's CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets. www.isogenica.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES